HIV-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents
AssigneesTemple University of the Commonwealth System of Higher Education, Board of Regents of the University of Nebraska
InventorsKamel Khalili, Howard E. Gendelman, Benson Edagwa
Life of this patent
Estimating the term…
Abstract
Methods of eliminating a retrovirus from a subject utilize nanoformulated anti-retroviral compounds and gene editing agents. Compositions comprise at least one anti-retroviral compounds, at least one gene-editing agent, or combinations thereof.
Claims14
A method of eradicating or eliminating a retrovirus in a subject, comprising administering to a patient a composition comprising a therapeutically effective amount of at least one antiretroviral agent, wherein the antiretroviral agent is formulated as a long-acting slow effective release (LASER) antiretroviral agent and a composition comprising a therapeutically effective amount of at least one gene editing agent, comprising an isolated nucleic acid sequence encoding:
- (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease/Cas9 (CRISPR/Cas9), and
- b) two or more guide RNAs, (i) a first guide RNA of the two or more guide RNAs being complementary to a first target nucleic acid sequence within a 5′- or 3′-long terminal repeat (LTR) of a human immunodeficiency virus sequence, and (ii) a second guide RNA of the two or more guide RNAs being complementary to a second target nucleic acid sequence within a group specific antigen (Gag) region of a human immunodeficiency virus sequence, wherein the first gRNA comprises SEQ ID NO:
- 303 and the second gRNA comprises SEQ ID NO:
- 304,
- thereby eradicating or eliminating the retrovirus in a subject.
Dependencies are inferred from the claim text.